Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Figure 1 Nab-paclitaxel mechanism of action.
A: After intravenous administration nab-paclitaxel is carried through bloodstream; B: Nab-paclitaxel binds gp60 albumin receptor on the endothelial cell; C: Endothelial transcytosis of nab-paclitaxel through the gp60 albumin receptor/caveolin - 1 pathway; D: Interaction between SPARC and nab-paclitaxel both on the pancreatic cancer cells and stromal fibroblasts. SPARC: Secreted protein acidic and rich in cysteine.
- Citation: Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886
- URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5875.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5875